Radical Honesty Is Part Of The Secret To Apellis's Success
On the heels of Apellis's wildly successful launch for the geographic atrophy drug Syfovre, the company's co-founder and CEO spoke with In Vivo about what it takes to go from a start-up to a commercial-stage company and about the importance of honesty in leadership.
You may also be interested in...
Apellis Set For Blockbuster Success With Syfovre, The First Approved Geographic Atrophy Drug
Around five million people worldwide suffer from geographic atrophy, and Apellis’s drug will be the first to offer hope of slowing the disease’s progress, as it reaches the US market at a price comparable to the VEGF inhibitors.
Apellis Aims New Pegcetacoplan Data At Market, Not Regulators
The company said the user fee goal date for pegcetacoplan in geographic atrophy would move from November to February as it submitted longer-term data.
Apellis Has New Hope for Pegcetacoplan With Longer-Term Data
One of two Phase III trials for pegcetacoplan in geographic atrophy previously failed, but 18-month data showed statistically significant and possibly accelerating improvement.